Scarica l'app Stockscreener
1.45
1.40%
0.02
Dopo l'orario di chiusura:
1.43
-0.02
-1.38%
Tscan Therapeutics Inc Borsa (TCRX) Ultime notizie
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference - GlobeNewswire
Cancer Therapy Pioneer TScan Therapeutics Set for Major Presentation at Jefferies Healthcare Conference - Stock Titan
TScan Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com Canada
TScan Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com
New Data and Deal Flow Signal a Turning Point for Precision-Driv - GuruFocus
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Comparing TScan Therapeutics (NASDAQ:TCRX) and Twist Bioscience (NASDAQ:TWST) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Cubist Systematic Strategies LLC - Defense World
Dimensional Fund Advisors LP Increases Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Stifel Financial Corp Acquires 10,567 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Barclays PLC - Defense World
H.C. Wainwright cuts Tscan stock target to $10, keeps Buy rating - Investing.com Nigeria
Equities Analysts Set Expectations for TCRX Q2 Earnings - Defense World
Research Analysts Set Expectations for TCRX FY2029 Earnings - Defense World
Wedbush Research Analysts Reduce Earnings Estimates for TCRX - Defense World
HC Wainwright Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $10.00 - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Position Trimmed by Renaissance Technologies LLC - Defense World
Brokers Offer Predictions for TCRX Q1 Earnings - Defense World
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates - MSN
TScan Therapeutics (TCRX) Price Target Lowered by HC Wainwright | TCRX Stock News - GuruFocus
What Analysts Are Saying About TScan Therapeutics Stock - Benzinga
TScan Therapeutics Reports Q1 2025 Financial Results - TipRanks
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
TScan Therapeutics (TCRX) Exceeds Q1 Revenue Expectations | TCRX Stock News - GuruFocus
TScan Therapeutics Reveals Solid Progress: Key Clinical Data Coming in 2025, $251M War Chest Secured - Stock Titan
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Average Target Price from Brokerages - Defense World
JPMorgan Chase & Co. Acquires 34,951 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
BlackRock, Inc. Reduces Stake in TScan Therapeutics Inc by 43.05% - GuruFocus
Geode Capital Management LLC Has $2.93 Million Stock Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting - Nasdaq
TScan Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting - Yahoo
What is the investor’s view on Tscan Therapeutics Inc (TCRX)? - uspostnews.com
Investing in Tscan Therapeutics Inc (TCRX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com
Prudential Financial Inc. Acquires Shares of 10,415 TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Average PT from Brokerages - Defense World
TScan Therapeutics’ (TCRX) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts - Benzinga
Monitoring Gentherm Inc (THRM) after recent insider movements - knoxdaily.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update - Defense World
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Tscan Therapeutics Inc [TCRX] Shares Fall Approximately -81.72% Over the Year - Knox Daily
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access - Quantisnow
Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - Stock Titan
TScan Therapeutics’ (TCRX) Overweight Rating Reiterated at Morgan Stanley - The AM Reporter
Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33 - Defense World
8.70%
1.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):